KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Debt to Equity (2018 - 2026)

Castle Biosciences' Debt to Equity history spans 6 years, with the latest figure at $0.02 for Q4 2025.

  • On a quarterly basis, Debt to Equity fell 2.87% to $0.02 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.02, a 2.87% decrease, with the full-year FY2025 number at $0.02, down 2.87% from a year prior.
  • Debt to Equity hit $0.02 in Q4 2025 for Castle Biosciences, down from $0.02 in the prior quarter.
  • Over the last five years, Debt to Equity for CSTL hit a ceiling of $0.05 in Q1 2022 and a floor of $0.02 in Q4 2025.
  • Historically, Debt to Equity has averaged $0.03 across 3 years, with a median of $0.02 in 2024.
  • The widest YoY moves for Debt to Equity: up 2.87% in 2025, down 8.3% in 2025.
  • Tracing CSTL's Debt to Equity over 3 years: stood at $0.05 in 2022, then tumbled by 58.1% to $0.02 in 2024, then dropped by 2.87% to $0.02 in 2025.
  • Business Quant data shows Debt to Equity for CSTL at $0.02 in Q4 2025, $0.02 in Q3 2025, and $0.02 in Q2 2025.